NASDAQ · KYMR
Kymera Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for KYMR has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-1.27 | $-1.02 | $-1.47 | 12 |
| Mar 2027 | $-1.38 | $-1.24 | $-1.51 | 4 |
| Jun 2027 | $-1.39 | $-1.21 | $-1.57 | 4 |
| Sep 2027 | $-1.36 | $-1.22 | $-1.57 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · Fintel · Zacks · Barchart- The Motley Fool · Oct 29, 4:44 PM EDTKymera (KYMR) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Oct 29, 1:42 PM EDTKymera Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Positive KT-579 Phase 1 Trial DataKymera Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, and announced positive results from its completed first-in-human KT-579 Phase 1 healthy volunteer trial. The trial of KT-579, an oral degrader of IRF5, demonstrated deep, sust
- Zacks · Oct 26, 9:00 AM EDTWill Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should KnowAxsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 19, 9:08 AM EDTCan KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
- Fintel · Oct 9, 3:40 PM EDTRaymond James Initiates Coverage of Kymera Therapeutics with Outperform RatingFintel reports that on October 9, 2026, Raymond James initiated coverage of Kymera Therapeutics (NASDAQGM:KYMR) with a Outperform recommendation. Prior to this rating action, the stock closed at $109.30 on October 8, 2026. Kymera Therapeutics has experienced a one-week price chan
- Barchart · Sep 10, 7:38 PM EDTStocks Retreat as 10-year T-note Yield Reaches New 2.75-year HighThe S&P 500 Index ($SPX ) (SPY ) is down -0.42% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.69%. E-mini S&P futures (ESU26 ) are down -0.40%, and September E-mini Nasdaq futures (NQU26…
- Barchart · Sep 10, 7:08 PM EDTStocks Slump as Crude Prices Soar and Bond Yields SurgeThe S&P 500 Index ($SPX ) (SPY ) is down -0.54% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.96%. E-mini S&P futures (ESU26 ) are down -0.50%, and September E-mini Nasdaq futures (NQU26…
- Zacks · Sep 4, 11:30 AM EDTKymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Sep 3, 11:50 AM EDTCan KT-621 Mark a Turning Point for Kymera Therapeutics?KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
- BNK Invest · Sep 3, 10:55 AM EDTState Street SPDR S&P Biotech ETF Experiences Big InflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $289.4 million dollar inflow — that's a 2.6% increase week
- The Motley Fool · Aug 12, 1:14 PM EDTKymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 6, 2:52 PM EDTKYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi PaymentsKymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Kymera Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.